CellWell record HH-47099
Lithium as a disease-modifying therapy for Parkinson's disease: mechanisms, preclinical evidence, and clinical prospects
Boonstra JT
Clinical parkinsonism & related disorders ยท 2026
In plain language
This review summarizes preclinical evidence that low-dose lithium preserves dopamine neurons, reduces microglial activation and alpha-synuclein pathology in Parkinson's disease models, with preliminary human microdose trials suggesting slowed progression but lacking phase 3 data.
- Evidence
- Emerging
- Design
- Expert review
Cite this record: https://thecellwell.org/studies/HH-47099
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.